Recent Quotes (30 days)

You have no recent quotes
chg | %

Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results forOREX
-0.01 (-0.43%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.30 - 2.37
52 week 1.65 - 5.70
Open 2.37
Vol / Avg. 0.00/71,672.00
Mkt cap 35.95M
P/E     -
Div/yield     -
EPS -7.05
Shares 15.43M
Beta 2.45
Inst. own 48%
Sep 27, 2017
Orexigen Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference - 4:35pm GMT-4 - Add to calendar
Sep 12, 2017
Orexigen Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Sep 7, 2017
Orexigen Therapeutics Inc at Wells Fargo Healthcare Conference
Aug 8, 2017
Q2 2017 Orexigen Therapeutics Inc Earnings Call - Webcast
Aug 8, 2017
Q2 2017 Orexigen Therapeutics Inc Earnings Release
Jul 7, 2017
Orexigen Therapeutics Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -130.66% -72.75%
Operating margin -179.78% -114.76%
EBITD margin - -149.03%
Return on average assets -57.42% -9.07%
Return on average equity - -54.24%
Employees 132 -
CDP Score - -


3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Officers and directors

Patrick J. Mahaffy Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Jason A. Keyes Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Thomas R. Cannell Chief Operating Officer, Executive Vice President, President - Global Commercial Products
Age: 55
Bio & Compensation  - Reuters
Thomas P. Lynch Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Peter Flynn Ph.D. Senior Vice President, Head - Development, Regulatory Affairs and Safety
Age: 43
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 52
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 75
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 52
Bio & Compensation  - Reuters
Peter K. Honig M.D. M.P.H. Independent Director
Age: 60
Bio & Compensation  - Reuters